Andrew Gianoukakis, MD
Endocrinology, Diabetes & Metabolism · Torrance, CANPI 1023083086
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Eisai Inc. at 45.7% of the total. Reporting peaked in 2021 at $17,626 and has fallen 90.6% since, to $1,656 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $779.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$23K
- Exelixis Inc.$16K
- Bayer$7K
- Blueprint Medicines Corporation$2K
- Eli Lilly$2K
- Pfizer$230
- plus $376 from 5 others
Across 147 payments — averaging $9926.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eisai Inc.$1M
- Exelixis Inc.$293K
- AstraZeneca$44K
- Roche Diagnostics Operations, Inc.$41K
- Eli Lilly$36K
- AbbVie$27K
- plus $12K from 3 others
What the payments were for
- Consulting fees$25,90652%
- Speaking & faculty fees$19,20538%
- Travel & lodging$3,2917%
- Food & beverage$1,5003%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 32 | $22,791 |
| Exelixis Inc. | 10 | $15,990 |
| Bayer | 7 | $6,769 |
| Blueprint Medicines Corporation | 1 | $2,240 |
| Eli Lilly | 3 | $1,505 |
| Pfizer | 4 | $230 |
| E.r. Squibb & Sons, L.L.C. | 1 | $150 |
| Sanofi | 1 | $125 |
| Amgen(2 entities) | 2 | $49 |
| Lilly USA, LLC | 2 | $29 |
| Johnson & Johnson | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$49,902 in reported general payments places this provider in the 90th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $6,370 |
| Pravastatin Sodium | 12 | $198 |
| Levothyroxine Sodium | 20 | $160 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Torrance
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.